Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of “Moderate Buy” from Analysts

Immunome, Inc. (NASDAQ:IMNM) has been assigned a consensus rating of “Moderate Buy” from the thirteen brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $33.1667.

Several equities analysts have weighed in on IMNM shares. Craig Hallum raised their price objective on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Immunome in a research note on Wednesday, May 13th. Finally, Barclays initiated coverage on Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price on the stock.

Insider Transactions at Immunome

In other news, CFO Max Rosett sold 60,000 shares of Immunome stock in a transaction on Monday, June 15th. The stock was sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the sale, the chief financial officer directly owned 54,037 shares in the company, valued at $985,094.51. The trade was a 52.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jean Jacques Bienaime bought 10,500 shares of the stock in a transaction dated Friday, June 5th. The shares were acquired at an average price of $19.45 per share, for a total transaction of $204,225.00. Following the completion of the purchase, the director directly owned 43,415 shares in the company, valued at approximately $844,421.75. This trade represents a 31.90% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 134,438 shares of company stock worth $2,722,838 in the last ninety days. Company insiders own 7.21% of the company’s stock.

Institutional Investors Weigh In On Immunome

A number of hedge funds have recently made changes to their positions in IMNM. Creative Planning raised its stake in Immunome by 4.0% in the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock valued at $219,000 after acquiring an additional 710 shares during the period. Russell Investments Group Ltd. raised its stake in Immunome by 14.4% in the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock valued at $159,000 after acquiring an additional 935 shares during the period. California State Teachers Retirement System raised its stake in Immunome by 1.8% in the 4th quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after acquiring an additional 1,167 shares during the period. Assetmark Inc. raised its stake in Immunome by 46.6% in the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after acquiring an additional 1,442 shares during the period. Finally, Virtus Investment Advisers LLC raised its stake in Immunome by 16.9% in the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after acquiring an additional 1,970 shares during the period. 44.58% of the stock is currently owned by institutional investors.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $19.96 on Monday. The stock’s fifty day simple moving average is $21.13 and its two-hundred day simple moving average is $21.72. Immunome has a 1-year low of $7.96 and a 1-year high of $27.65. The stock has a market cap of $2.26 billion, a PE ratio of -8.39 and a beta of 2.04.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12. On average, sell-side analysts forecast that Immunome will post -2.06 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.